Literature DB >> 11503969

Lupus anticoagulant-like activity observed in a dimeric lambda protein produced by myeloma cells.

A Shinagawa1, H Kojima, T Kobayashi, K Kawada, T Nagasawa.   

Abstract

We report here a lupus anticoagulant (LA)-like activity observed in a 45-year-old man with Bence-Jones protein (BJP) lambda-type multiple myeloma. This patient showed no clinical symptoms of thrombosis or bleeding diathesis. Laboratory examination on admission showed mild anemia, prolongation of activated partial thromboplastin time (APTT) (APTT, 56.2 seconds; control, 29.1 seconds), normal prothrombin time, normal thrombin time, and massive proteinuria (2.3 g/d). The mix test with normal plasma showed the presence of circulating anticoagulant. Based on the assumption that the lambda-type BJP may have been responsible for the prolongation of APTT, we purified the BJP from the patient's urine using column works. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting showed that the purified protein was a 48-kd homodimer of immunoglobulin lambda-chains. Addition of the purified dimeric lambda-type BJP to the normal plasma prolonged both APTT and dilute Russell's viper venom time (DRVVT) in a dose-dependent manner, and the negatively charged phospholipid-dependent prothrombinase activity was significantly inhibited in the presence of this protein. Furthermore, both the prolongation of DRVVT and the inhibition of the prothrombinase activity were almost completely abrogated under the condition of high ionic strength. These findings collectively suggest that the dimeric lambda-type BJP showed LA-like activity via the mechanism of ionic charge.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11503969     DOI: 10.1007/bf02994017

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  14 in total

1.  Light-chain paraproteins with lupus anticoagulant activity.

Authors:  Z Yasin; D Quick; P Thiagarajan; D Spoor; J Caraveo; J Palascak
Journal:  Am J Hematol       Date:  1999-10       Impact factor: 10.047

2.  Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants.

Authors:  T Exner; D A Triplett; D Taberner; S J Machin
Journal:  Thromb Haemost       Date:  1991-03-04       Impact factor: 5.249

Review 3.  Current insights into the "antiphospholipid" syndrome: clinical, immunological, and molecular aspects.

Authors:  D A Kandiah; A Sali; Y Sheng; E J Victoria; D M Marquis; S M Coutts; S A Krilis
Journal:  Adv Immunol       Date:  1998       Impact factor: 3.543

4.  Study of three patients with monoclonal gammopathies and 'lupus-like' anticoagulants.

Authors:  V Bellotti; G Gamba; G Merlini; N Montani; E Bucciarelli; M Stoppini; E Ascari
Journal:  Br J Haematol       Date:  1989-10       Impact factor: 6.998

5.  Hemostatic defects in dysproteinemias.

Authors:  H A Perkins; M R MacKenzie; H H Fudenberg
Journal:  Blood       Date:  1970-05       Impact factor: 22.113

6.  Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids.

Authors:  H Takeya; T Mori; E C Gabazza; K Kuroda; H Deguchi; E Matsuura; K Ichikawa; T Koike; K Suzuki
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

7.  Relationship between clinical features and binding domains of anti-prothrombin autoantibodies in patients with systemic lupus erythematosus and antiphospholipid syndrome.

Authors:  T Akimoto; T Akama; I Kono; T Sumida
Journal:  Lupus       Date:  1999       Impact factor: 2.911

8.  Acquired von Willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand factor.

Authors:  H Mohri; T Noguchi; F Kodama; A Itoh; T Ohkubo
Journal:  Am J Clin Pathol       Date:  1987-05       Impact factor: 2.493

9.  Platelet functions in dysproteinaemia.

Authors:  J Kasturi; A K Saraya
Journal:  Acta Haematol       Date:  1978       Impact factor: 2.195

10.  Acquired type II von Willebrand's disease: demonstration of a complexed inhibitor of the von Willebrand factor-platelet interaction and response to treatment.

Authors:  J Goudemand; B Samor; C Caron; B Jude; D Gosset; C Mazurier
Journal:  Br J Haematol       Date:  1988-02       Impact factor: 6.998

View more
  3 in total

Review 1.  Thrombotic complications in multiple myeloma: a report of three cases and review of the literature.

Authors:  Yonal Ipek; Hindilerden Fehmi; Besisik-Kalayoglu Sevgi; Sargin Deniz
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

2.  Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.

Authors:  Kathrin Andrich; Ute Hegenbart; Christoph Kimmich; Niraja Kedia; H Robert Bergen; Stefan Schönland; Erich Wanker; Jan Bieschke
Journal:  J Biol Chem       Date:  2016-12-28       Impact factor: 5.157

3.  Acquired heparin-like anticoagulation process in a patient with multiple myeloma: a case report and literature review.

Authors:  Haorui Shen; Chao Wu; Lijuan Chen; Run Zhang
Journal:  Transl Cancer Res       Date:  2020-11       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.